NetworkNewsBreaks

WednesdayDec 23, 2020 10:54 am

NetworkNewsBreaks – Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) Announces Addition to CSE Composite Index, CSE25 Index

Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), an investment company, has been added to two Canadian Securities Exchange (“CES”) indices: the CSE Composite Index(r) as well as the CSE25(TM) (“CSE25”) index. The CSE Composite Index includes coverage of about 75% of all equities listed on the CSE; much of the index consists of life sciences firms. The CSE25 index is a division of the CSE Composite Index and is comprised of securities of the top-25 companies  determined by market capitalization, including MOVE; as of pre-open on Dec. 22, 2020, the CSE25 has a combined portfolio capitalization of about CAD$28.1…

Continue Reading

WednesdayDec 23, 2020 10:38 am

NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Closes $100M Underwritten Public Offering

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the closing of its $100 million underwritten public offering. The offering consisted of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share, and 2,000,000 shares of its Series D convertible preferred stock at a public offering price of $21.16 per share. All of the securities in the offering were sold by VistaGen. Acuta Capital, New Enterprise Associates (“NEA”), OrbiMed and Venrock Healthcare Capital Partners, among others, participated in…

Continue Reading

WednesdayDec 23, 2020 10:20 am

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters into Estimated $12-Million Securities Purchase Agreement

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor. The agreement outlines the purchase and sale of 3,116,884 shares of Genprex common stock; the purchase price of those shares will be $3.85 per share in a registered direct offering priced at-the-market under Nasdaq rules. The agreement, which is expected to close on or before Dec. 24, 2020, also stipulates that no warrants will be issued in connection with the transaction. The offering closing is subject to the…

Continue Reading

WednesdayDec 23, 2020 9:00 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of $10M Public Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock. According to the update, the shares of common stock and warrants are being sold together at a combined public offering price of $2.00 per share and warrant. The warrants will have an exercise price of $2.20 per share and will be immediately exercisable and expire five years from…

Continue Reading

TuesdayDec 22, 2020 3:31 pm

NetworkNewsBreaks – Rritual Superfoods Inc. Eyes Growing Opportunity in Nascent Functional Mushrooms Market

Rritual, a plant-based consumer brand, is set to take advantage of opportunity as functional mushrooms move mainstream. Within the rapidly emerging functional foods industry, the functional mushrooms sector is projected to increase at a CAGR of 5.6% during 2021–2026 and reach $24.85 billion by the end of the forecast period. “Founded in 2019, Rritual has, to date, brought three mushroom-based products to market and is in the process of developing others. Rritual is working to ensure that its offerings not only augment the physical and psychological condition of consumers but also provide a healthy return for shareholders,” states a recent…

Continue Reading

TuesdayDec 22, 2020 2:57 pm

NetworkNewsBreaks – Why RYAH Group Inc. Is ‘One to Watch’

RYAH Group is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through its IoT dose-measuring devices and AI analytics, RYAH is focused on expanding understanding of the value of devices combined with data to positively impact the future treatment of patients for various medical conditions. A recent article discussing the company reads, “Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed…

Continue Reading

TuesdayDec 22, 2020 2:42 pm

NetworkNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Takes Game-Changing Visualization Method to the Next Level

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is at the forefront of change in its focus to establish a new standard of care in visualizing cancer. Minimally invasive surgery (“MIS”) using white light to illuminate tumor growth is the current standard of care for bladder cancer. This method is highly effective for visualizing cancerous tumors that protrude above the bladder’s wall. However, due to the difficulty in distinguishing flat tumors from normal tissue, it is nearly impossible to visualize the margins of the tumor under current standards. Game-changing to the industry has been the introduction of blue…

Continue Reading

TuesdayDec 22, 2020 2:29 pm

NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Aims to Identify Best Delivery Method for Lead Drug Candidate

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, recently submitted a protocol amendment request to the U.S. Food and Drug Administration (“FDA”). Approval of the amendment will allow AzurRx to modify its current Phase 2b OPTION 2 trial of MS1819 in cystic fibrosis (“CF”) patients to add a study arm that uses immediate release capsules (https://nnw.fm/ADfpm). The existing study arm uses delayed release capsules, so the expansion will allow AzurRx to compare data from both arms to determine the best delivery method for its lead product, an exocrine pancreatic insufficiency…

Continue Reading

TuesdayDec 22, 2020 2:18 pm

NetworkNewsBreaks – Noble Capital Markets Inc. Announces Launch of Investor Outreach Campaign for NobleCon17

Noble Capital Markets today announced that it will begin its marketing campaign to investors for its 17th Annual Small & Microcap Investor Conference (NobleCon17) to be held virtually from Jan.19 - 20, 2021. Noble expects more than 100 presenting companies and, while it hoped to continue its long tradition to host this preeminent event in-person, is focused on creating a best-in-class virtual experience for both public companies and investors. To do this, Noble will again employ the award-winning video-webcasting technology of Mediasite. In 2005, Noble revolutionized conference webcasting with this HD video technology and has since used it at all…

Continue Reading

TuesdayDec 22, 2020 1:54 pm

NetworkNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Poised in Convergence of Digital Technologies, Engagement

SRAX (NASDAQ: SRAX), focused on unlocking data and insights through its software-as-a-service (“Saas”) platform, Sequire, is emerging as a leader within the investor intelligence field. Launched as a stand-alone platform in early 2020, Sequire has amassed over 1 million investors and traders and has attracted over 91 publicly listed companies as subscribers. The explosion in growth is largely driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike. A recent article discussing this reads,…

Continue Reading